{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:50:19Z","timestamp":1779886219821,"version":"3.53.1"},"reference-count":16,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011000","name":"Mission Interminist\u00e9rielle de Lutte Contre les Drogues et les Conduites Addictives","doi-asserted-by":"publisher","award":["PREVDROG"],"award-info":[{"award-number":["PREVDROG"]}],"id":[{"id":"10.13039\/501100011000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009506","name":"universite paris 13","doi-asserted-by":"publisher","award":["PREVDROG"],"award-info":[{"award-number":["PREVDROG"]}],"id":[{"id":"10.13039\/501100009506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>(1) Background: Opioid use disorder (OUD) is a complex condition that can require long-term treatment. Pharmacological therapy for OUD involves treatment with opioid agonists (OMT) tailored to individual profiles. The aim of our study in daily clinical practice was to compare the profiles of patients treated with methadone (MTD) and those using buprenorphine (BHD or BHD-naloxone-NX). (2) Methods: A cross-sectional multicentre study explored the psychological, somatic and social profiles of patients with Opioid Use Disorder (OUD) following Opioid Maintenance Treatment (BHD, BHD\/NX, or MTD). Descriptive and comparative analyses were performed (3) Results: 257 patients were included, a majority were men using heroin. 68% (178) were on MTD, 32% (79) were on BHD. Patients with MTD were significantly more likely to report socio-affective damage, and more likely to be younger and not to report oral or sublingual use as the main route for heroin or non-medical opioids (4) Conclusions: In daily clinical practice, regarding OUD damage, only socio-affective damage was significantly more prevalent among patients on MTD than among those on BHD in the multivariate model. Age and route of administration also differed, and our results could raise the issue of the type of OMT prescribed in case of non-medical use of prescribed opioids. These hypothesis should be confirmed in larger studies.<\/jats:p>","DOI":"10.3390\/ijerph18041425","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T20:31:51Z","timestamp":1612384311000},"page":"1425","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report"],"prefix":"10.3390","volume":"18","author":[{"given":"Morgane","family":"Guillou-Landreat","sequence":"first","affiliation":[{"name":"INSERM UMR 1246, SPHERE, Methods in Patient-Centered Outcomes and Health Research, Nantes and Tours Universities, 44000 Nantes, France"},{"name":"EA 7479 SPURBO, Universite Bretagne Occidentale, 29200 Brest, France"},{"name":"HUGOPSY Network, 35000 Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-9738","authenticated-orcid":false,"given":"Antoine","family":"Dany","sequence":"additional","affiliation":[{"name":"EA 7479 SPURBO, Universite Bretagne Occidentale, 29200 Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2238-8005","authenticated-orcid":false,"given":"Ga\u00eblle","family":"Challet-Bouju","sequence":"additional","affiliation":[{"name":"INSERM UMR 1246, SPHERE, Methods in Patient-Centered Outcomes and Health Research, Nantes and Tours Universities, 44000 Nantes, France"},{"name":"CHU Nantes, Addictology and Psychiatry Department, Nantes University Hospital, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7400-1212","authenticated-orcid":false,"given":"Edouard","family":"Laforgue","sequence":"additional","affiliation":[{"name":"INSERM UMR 1246, SPHERE, Methods in Patient-Centered Outcomes and Health Research, Nantes and Tours Universities, 44000 Nantes, France"},{"name":"CHU Nantes, Addictology and Psychiatry Department, Nantes University Hospital, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Leboucher","sequence":"additional","affiliation":[{"name":"CHU Nantes, Addictology and Psychiatry Department, Nantes University Hospital, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8664-623X","authenticated-orcid":false,"given":"Jean","family":"Benoit Hardouin","sequence":"additional","affiliation":[{"name":"INSERM UMR 1246, SPHERE, Methods in Patient-Centered Outcomes and Health Research, Nantes and Tours Universities, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Victorri-Vigneau","sequence":"additional","affiliation":[{"name":"INSERM UMR 1246, SPHERE, Methods in Patient-Centered Outcomes and Health Research, Nantes and Tours Universities, 44000 Nantes, France"},{"name":"CHU Nantes, Pharmacology Department, Nantes University Hospital, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-7243","authenticated-orcid":false,"given":"Marie","family":"Grall-Bronnec","sequence":"additional","affiliation":[{"name":"INSERM UMR 1246, SPHERE, Methods in Patient-Centered Outcomes and Health Research, Nantes and Tours Universities, 44000 Nantes, France"},{"name":"HUGOPSY Network, 35000 Rennes, France"},{"name":"CHU Nantes, Addictology and Psychiatry Department, Nantes University Hospital, 44000 Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: Recommendations and rationale","volume":"170","author":"Hasin","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3122\/jabfm.2014.03.130290","article-title":"Risk of adverse health outcomes with increasing duration and regularity of opioid therapy","volume":"27","author":"Paulozzi","year":"2014","journal-title":"J. Am. Board. Fam. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","article-title":"Recommendations for buprenorphine and methadone therapy in opioid use disorder: A European consensus","volume":"18","author":"Dematteis","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Landreat, M.G., Rozaire, C., Guillet, J.Y., Vigneau, C.V., Le Reste, J.Y., and Bronnec, M.G. (2015). French Experience with Buprenorphine: Do Physicians Follow the Guidelines?. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137708"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","article-title":"Why buprenorphine is so successful in treating opiate addiction in France","volume":"9","author":"Fatseas","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"ANAES (2004). Strat\u00e9gies th\u00e9rapeutiques pour les personnes d\u00e9pendantes des opiac\u00e9s: Place des traitements de substitution. Presse M\u00e9d., 33, 41\u201347.","DOI":"10.1016\/S0755-4982(04)72381-7"},{"key":"ref_7","unstructured":"British Columbia Centre on Substance Use and British Columbia Ministry of Health (C.O.P.A.S.O.B.) (2017). Methadone and Buprenorphine: Clinical Practice Guideline for Opioid Use Disorder, British Columbia Centre on Substance Use and British Columbia Ministry of Health."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fpsyt.2019.00726","article-title":"Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients with Long-Term Opioid Substitution Therapy: The OPAL Study","volume":"10","author":"Laforgue","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/bcp.13936","article-title":"Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study","volume":"85","author":"Verstuyft","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","article-title":"The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire","volume":"86","author":"Heatherton","year":"1991","journal-title":"Br. J. Addict."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.lpm.2007.01.005","article-title":"Validation of a questionnaire to screen for harmful use of alcohol and cannabis in the general population: CRAFFT-ADOSPA","volume":"36","author":"Karila","year":"2007","journal-title":"Presse Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2466\/pr0.1997.80.1.83","article-title":"The Lie\/Bet Questionnaire for screening pathological gamblers","volume":"80","author":"Johnson","year":"1997","journal-title":"Psychol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Maremmani, A.G.I., Pacini, M., and Maremmani, I. (2019). What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16030447"},{"key":"ref_14","unstructured":"INPES (2009). Barom\u00e8tre Sant\u00e9 M\u00e9decins G\u00e9n\u00e9ralistes, INPES."},{"key":"ref_15","unstructured":"OFDT (2019). Drogues, Chiffres Cl\u00e9s, OFDT. [8th ed.]."},{"key":"ref_16","unstructured":"Brisacier, A. (2018). Tableau de Bord \u00abTraitements de Substituion aux Opiac\u00e9s\u00bb, OFDT."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/4\/1425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:19:46Z","timestamp":1760159986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/4\/1425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijerph18041425"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18041425","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}